Serum ADAM12 as a Biomarker in Fibromyalgia Syndrome: Inflammatory and Clinical Correlates

Tugba Agbektas; Emrulah Hayta; Yavuz Siliğ

doi:10.17776/csj.1781092

Serum ADAM12 as a Biomarker in Fibromyalgia Syndrome: Inflammatory and Clinical Correlates

Abstract

Fibromyalgia syndrome (FMS) is characterized by widespread pain accompanied by fatigue, sleep disturbance, and cognitive symptoms. This cross-sectional study included 44 patients with FMS and 43 age- and gender-matched healthy controls. Serum A Disintegrin and Metalloprotease 12 (ADAM12) levels were measured by immunoassay, and clinical features were recorded. ADAM12 concentrations were significantly higher in the FMS group than in controls (1041.15 ± 565.09 ng/L vs. 834.05 ± 365.56 ng/L; p = 0.004). ROC analysis showed modest diagnostic performance (AUC = 0.678; p = 0.004). Sleep disturbance, fatigue, and concentration difficulties were more prevalent in patients. Family history of FMS occurred only in patients and was associated with higher ADAM12 (p = 0.010). ADAM12 also correlated with age (p = 0.047) and family history (p = 0.024). ADAM12, despite its limited standalone diagnostic value, emerges as a promising supplementary biomarker in FMS, with its elevation and clinical associations underscoring the need for further validation in longitudinal studies.

Keywords

ADAM12, Biomarker, Correlation analysis, FMS, Immunoassay

Ethical Statement

Ethical approval for the research was granted by the Local Research and Ethics Committee of Sivas Cumhuriyet University on January 15, 2020 (Approval No: 2020-01/26)

References

[1] Metyas, S., Arkfeld, D. G., & Aslam, S. (2017). Autoinflammation and immunomodulation in inflammatory fibromyalgia syndrome — A review. Current Rheumatology Reviews, 13(2), 98–102. http://dx.doi.org/10.2174/1573397112666160919120530
[2] Helmick, C. G., Felson, D. T., Lawrence, R. C., Gabriel, S., Hirsch, R., Kwoh, C. K., Liang, M. H., Kremers, H. M., Mayes, M. D., Merkel, P. A., Pillemer, S. R., Reveille, J. D., & Stone, J. H. (2008). Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I. Arthritis & Rheumatism, 58(1), 15–25. https://doi.org/10.1002/art.23177
[3] Kim, S.-H., Kim, D.-H., Oh, D.-H., & Clauw, D. J. (2008). Characteristic electron microscopic findings in the skin of patients with fibromyalgia — Preliminary study. Clinical Rheumatology, 27(2), 219–223. https://doi.org/10.1007/s10067-007-0683-1
[4] Zheng, C., & Zhou, T. J. (2022). Effect of acupuncture on pain, fatigue, sleep, physical function, stiffness, well-being, and safety in fibromyalgia: A systematic review and meta-analysis. Journal of Pain Research, 15, 315–329. https://doi.org/10.2147/JPR.S351320
[5] Wilson, J. M., Smith, B. H., & McBeth, J. (2024). The role of sleep disturbance in reduced accuracy on a divided attention task among patients with fibromyalgia. Pain Medicine, 25(1), e1122. https://doi.org/10.1093/pm/pnad124
[6] Soldatelli, M., Dos Santos, F. S., & da Silveira, C. K. (2023). Primary somatosensory cortex and periaqueductal gray functional connectivity as a marker of the dysfunction of the descending pain modulatory system in fibromyalgia. Pain, 36(1), 113–127.
[7] Aziz, Q., Giamberardino, M. A., & Barke, A. (2019). The IASP classification of chronic pain for ICD-11: Chronic secondary visceral pain. Pain, 160(1), 69–76. https://doi.org/10.1097/j.pain.0000000000001362
[8] Teodoro, T., Edwards, M. J., & Isaacs, J. D. (2018). A unifying theory for cognitive abnormalities in functional neurological disorders, fibromyalgia and chronic fatigue syndrome: Systematic review. Journal of Neurology, Neurosurgery & Psychiatry, 89(12), 1308–1319. https://doi.org/10.1136/jnnp-2017-317823
[9] Lichtenstein, A., Tiosano, S., & Amital, H. (2018). Cross-sectional analysis of the associations between fibromyalgia and diabetes mellitus. Israel Medical Association Journal, 56(5), 275–278.
[10] Azarfar, A., Ahmed, A., & Bég, S. (2021). Prevalence of anxiety, depression, sleep disturbance, fibromyalgia, obesity, and gastroesophageal disease in patients with rheumatic diseases. Current Rheumatology Reviews, 17(2), 252–257. http://dx.doi.org/10.2174/1573397116666201211124815

[11] Siracusa, R., Di Paola, R., Cuzzocrea, S., & Impellizzeri, D. (2021). Fibromyalgia: Pathogenesis, mechanisms, diagnosis and treatment options update. International Journal of Molecular Sciences, 22(8), 3891. https://doi.org/10.3390/ijms22083891
[12] Romanov, D. V., Pavlova, M. V., & Filatova, E. S. (2023). Personality disorders and traits of ABC clusters in fibromyalgia in a neurological setting. Journal of Clinical Medicine, 12(12), 3162. https://doi.org/10.3390/biomedicines11123162
[13] Flynn, D. J. (2023). Chronic pain syndromes: Fibromyalgia. Forensic Science, 533, 7–15.
[14] Ghafouri, B., Gerdle, B., & Ghafouri, N. (2023). The vastus lateralis muscle interstitium proteome changes after an acute nociception in patients with fibromyalgia compared to healthy subjects — A microdialysis study. Biomolecules, 13(1), 206. https://doi.org/10.3390/biomedicines11010206
[15] Mahdi, A. A., & Fatima, G. J. (2014). A quest for better understanding of biochemical changes in fibromyalgia syndrome. International Journal of Clinical Biochemistry, 1–2. https://doi.org/10.1007/s12291-013-0395-z
[16] Ovrom, E. A., Alhawamdeh, M., & Park, H. J. (2023). A comprehensive review of the genetic and epigenetic contributions to the development of fibromyalgia. Genes (Basel), 14(4), 1119. https://doi.org/10.3390/biomedicines11041119
[17] García Rodríguez, D. F., & Abud Mendoza, C. (2020). Fisiopatología de la fibromialgia. Reumatología Clínica, 16(3), 191–194. https://doi.org/10.1016/j.reuma.2020.02.003
[18] Devigili, G., Rinaldo, S., & Lombardi, R. (2023). Clinical criteria and diagnostic assessment of fibromyalgia: Position statement of the Italian Society of Neurology-Neuropathic Pain Study Group. Neurological Sciences, 44(7), 2561–2574. https://doi.org/10.1007/s10072-023-06836-3
[19] Bruun, K. D., Amris, K., & Vaegter, H. B. (2022). Performance of the 2016 diagnostic criteria for fibromyalgia in a tertiary care pain rehabilitation setting: A diagnostic accuracy study. BMC Musculoskeletal Disorders, 23(1), 67–76. https://doi.org/10.1515/sjpain-2021-0081
[20] Pontes-Silva, A. J. (2024). Fibromyalgia: A new set of diagnostic criteria based on the biopsychosocial model. Rheumatology (Oxford), 63(7), 2037–2039. https://doi.org/10.1093/rheumatology/keae074
[21] Demori, I., Ruggiero, V., & Sanna, A. (2022). Thalamocortical bistable switch as a theoretical model of fibromyalgia pathogenesis inferred from a literature survey. Journal of Integrative Neuroscience, 21(4), 471–484. https://doi.org/10.1007/s10827-022-00826-8
[22] Sarzi-Puttini, P., Giorgi, V., & Atzeni, F. (2020). Fibromyalgia: An update on clinical characteristics, aetiopathogenesis and treatment. Nature Reviews Rheumatology, 16(11), 645–660. https://doi.org/10.1038/s41584-020-00506-w
[23] Wewer, U. M. (2004). ADAM12. In Handbook of proteolytic enzymes (pp. 724–726). Elsevier.
[24] Lendeckel, U., Kahne, T., & Ittenson, A. (2015). Effects of nitric oxide synthase deficiency on a disintegrin and metalloproteinase domain-containing protein 12 expression in mouse brain samples. Nitric Oxide, 12(2), 2253–2262. https://doi.org/10.3892/mmr.2015.3643
[25] Hougaard, S., Loechel, F., & Xu, X. (2000). Trafficking of human ADAM 12-L: Retention in the trans-Golgi network. Journal of Biological Chemistry, 275(2), 261–267. https://doi.org/10.1006/bbrc.2000.3295
[26] Gilpin, B. J., Loechel, F., & Mattei, M. G. (1998). A novel, secreted form of human ADAM 12 (meltrin α) provokes myogenesis in vivo. Journal of Biological Chemistry, 273(1), 157–166. https://doi.org/10.1074/jbc.273.1.157
[27] Bornemann, A., Schmalbruch, H., & Yamada, T. (2000). Analysis for transcript expression of meltrin α in normal, regenerating, and denervated rat muscle. Journal of Muscle Research and Cell Motility, 21, 475–480. https://doi.org/10.1023/A:1005657607591
[28] Kveiborg, M., Albrechtsen, R., & Couchman, J. R. (2006). ADAM12‐S stimulates bone growth in transgenic mice by modulating chondrocyte proliferation and maturation. Journal of Bone and Mineral Research, 21(8), 1288–1296. https://doi.org/10.1359/jbmr.060502
[29] Verrier, S., Hogan, A., & McKie, N. (2004). ADAM gene expression and regulation during human osteoclast formation. Bone, 35(1), 34–46. https://doi.org/10.1016/j.bone.2003.12.029
[30] Cao, Y., Kang, Q., & Zolkiewska, A. (2003). Role of metalloprotease disintegrin ADAM12 in determination of quiescent reserve cells during myogenic differentiation in vitro. Molecular and Cellular Biology, 23(19), 6725–6738. https://doi.org/10.1128/MCB.23.19.6725-6738.2003
[31] Kawaguchi, N., Sundberg, C., & Kveiborg, M. (2003). ADAM12 induces actin cytoskeleton and extracellular matrix reorganization during early adipocyte differentiation by regulating β1 integrin function. Journal of Cell Science, 116(19), 3893–3904. https://doi.org/10.1242/jcs.00699
[32] Le Pabic, H., Bonnier, D., & Wewer, U. M. (2003). ADAM12 in human liver cancers: TGF‐β‐regulated expression in stellate cells is associated with matrix remodeling. Hepatology, 37(5), 1056–1066. https://doi.org/10.1053/jhep.2003.50205
[33] Zhang, L., Wang, X. E., & Wang, H. (2009). Adam12 plays a role during uterine decidualization in mice. Development, 338(3), 413–421.
[34] Bernstein, H. G., Keilhoff, G., & Bukowska, A. (2004). ADAM (a disintegrin and metalloprotease) 12 is expressed in rat and human brain and localized to oligodendrocytes. Journal of Neuroscience Research, 75(3), 353–360. https://doi.org/10.1002/jnr.10857
[35] Ahmed, S., Aggarwal, A., & Lawrence, A. (2019). Performance of the American College of Rheumatology 2016 criteria for fibromyalgia in a referral care setting. Rheumatology International, 39(8), 1397–1403. https://doi.org/10.1007/s00296-019-04323-7
[36] Nyren-Erickson, E. K., Stutzman, J. R., & Bai, S. (2013). A disintegrin and metalloproteinase-12 (ADAM12): Function, roles in disease progression, and clinical implications. Biochimica et Biophysica Acta, 1830(10), 4445–4455.
[37] Moncada-Pazos, A., Obaya, A. J., & Llamazares, M. (2012). ADAMTS-12 metalloprotease is necessary for normal inflammatory response. Journal of Biological Chemistry, 287(47), 39554–39563. https://doi.org/10.1074/jbc.M112.408625
[38] Tas, A., Gunduz, O. H., & Yilmaz, H. (2023). Investigation of early growth response protein (EGR) levels in patients with fibromyalgia syndrome: A cross-sectional study. Archives of Rheumatology, 38(12), 1001–1008. http://dx.doi.org/10.2174/0109298665256584231103113328
[39] Oh, S., Kim, J. H., & Park, S. H. (2025). A disintegrin and metallopeptidase domain (ADAM) 12, ADAM 17 mRNA and ADAM10 protein hold potential as biomarkers for detection of early gastric cancer. Scientific Reports, 15(1), 763. https://doi.org/10.1038/s41598-024-84237-y
[40] Wu, Z., Chen, J., & Luo, H. (2017). The association of ADAM12 polymorphism with osteoarthritis susceptibility: A meta-analysis. Journal of Orthopaedic Surgery and Research, 12, 821–830.
[41] Okada, A., Mochizuki, S., & Yatabe, T. (2008). ADAM‐12 (meltrin α) is involved in chondrocyte proliferation via cleavage of insulin‐like growth factor binding protein 5 in osteoarthritic cartilage. Arthritis & Rheumatism, 58(3), 778–789. https://doi.org/10.1002/art.23262

Details

Primary Language

English

Subjects

Analytical Biochemistry, Cell Metabolism, Cellular Interactions

Journal Section

Research Article

Authors

Tugba Agbektas ^*
0000-0003-3433-8870
Türkiye

Emrulah Hayta
0000-0001-9460-9404
Türkiye

Yavuz Siliğ
0000-0002-0562-7457
Türkiye

Publication Date

February 27, 2026

Submission Date

September 10, 2025

Acceptance Date

January 15, 2026

Published in Issue

Year 2026 Volume: 47 Number: 1

DOI

https://doi.org/10.17776/csj.1781092

IZ

https://izlik.org/JA69ZF33DX

APA

Agbektas, T., Hayta, E., & Siliğ, Y. (2026). Serum ADAM12 as a Biomarker in Fibromyalgia Syndrome: Inflammatory and Clinical Correlates. Cumhuriyet Science Journal, 47(1), 9-16. https://doi.org/10.17776/csj.1781092

AMA

1.Agbektas T, Hayta E, Siliğ Y. Serum ADAM12 as a Biomarker in Fibromyalgia Syndrome: Inflammatory and Clinical Correlates. CSJ. 2026;47(1):9-16. doi:10.17776/csj.1781092

Chicago

Agbektas, Tugba, Emrulah Hayta, and Yavuz Siliğ. 2026. “Serum ADAM12 As a Biomarker in Fibromyalgia Syndrome: Inflammatory and Clinical Correlates”. Cumhuriyet Science Journal 47 (1): 9-16. https://doi.org/10.17776/csj.1781092.

EndNote

Agbektas T, Hayta E, Siliğ Y (February 1, 2026) Serum ADAM12 as a Biomarker in Fibromyalgia Syndrome: Inflammatory and Clinical Correlates. Cumhuriyet Science Journal 47 1 9–16.

IEEE

[1]T. Agbektas, E. Hayta, and Y. Siliğ, “Serum ADAM12 as a Biomarker in Fibromyalgia Syndrome: Inflammatory and Clinical Correlates”, CSJ, vol. 47, no. 1, pp. 9–16, Feb. 2026, doi: 10.17776/csj.1781092.

ISNAD

Agbektas, Tugba - Hayta, Emrulah - Siliğ, Yavuz. “Serum ADAM12 As a Biomarker in Fibromyalgia Syndrome: Inflammatory and Clinical Correlates”. Cumhuriyet Science Journal 47/1 (February 1, 2026): 9-16. https://doi.org/10.17776/csj.1781092.

JAMA

1.Agbektas T, Hayta E, Siliğ Y. Serum ADAM12 as a Biomarker in Fibromyalgia Syndrome: Inflammatory and Clinical Correlates. CSJ. 2026;47:9–16.

MLA

Agbektas, Tugba, et al. “Serum ADAM12 As a Biomarker in Fibromyalgia Syndrome: Inflammatory and Clinical Correlates”. Cumhuriyet Science Journal, vol. 47, no. 1, Feb. 2026, pp. 9-16, doi:10.17776/csj.1781092.

Vancouver

1.Tugba Agbektas, Emrulah Hayta, Yavuz Siliğ. Serum ADAM12 as a Biomarker in Fibromyalgia Syndrome: Inflammatory and Clinical Correlates. CSJ. 2026 Feb. 1;47(1):9-16. doi:10.17776/csj.1781092

As of 2026, Cumhuriyet Science Journal will be published in six issues per year, released in February, April, June, August, October, and December

Serum ADAM12 as a Biomarker in Fibromyalgia Syndrome: Inflammatory and Clinical Correlates

Abstract

Keywords

Ethical Statement

References

Details

Primary Language

Subjects

Journal Section

Authors

Publication Date

Submission Date

Acceptance Date

Published in Issue

DOI

IZ

Cite